Association between KIR3DS1 genotype and PFS. (A) PFS for GR patients who were KIR3DS1⁺ was significantly shorter than for GR patients who were KIR3DS1⁻ (P = .003). The median PFS for poor-risk patients was not significantly different from GR, KIR3DS1⁺ patients (P = .061). (B) Among patients with GR disease at ASCT, those with KIR3DS1⁺/KIR3DL1⁺/HLA-Bw4⁻ have significantly reduced PFS than patients with KIR3DS1⁺/KIR3DL1⁺/HLA-Bw4⁺ and patients with KIR3DS1⁻ irrespective of HLA-Bw4 (P = .002).